The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer

Demir L., Somali I., Tarhan M. O., Erten C., ELLİDOKUZ H., Can A., ...Daha Fazla

JOURNAL OF BUON, cilt.16, sa.4, ss.682-688, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 4
  • Basım Tarihi: 2011
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.682-688
  • Anahtar Kelimeler: adjuvant treatment, colon cancer, efficacy, Nordic-FLOX regimen, toxicity
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Purpose: To evaluate the toxicity and efficacy of oxaliplatin combined with the Nordic regimen of bolus 5-fluorouracil (5-FU) and leucovorin (LT) (Nordic-FLOX) as adjuvant treatment in stage III colon cancer patients. Methods: Fifty-three patients with resected stage III colon cancer were treated with adjuvant bolus Nordic-FLOX regimen (oxaliplatin 85 mg/m(2) on day 1, bolus 5-FU 500 mg/m(2) and bolus LV 60 mg/m(2) days 1 and 2) every 2 weeks for 12 cycles. Results: The probability of disease-free survival (DFS) at a median follow-up time of 29 months was 72%. Relapse was seen in 13 (24.5%) patients. The probability of 3-year overall survival (OS) at 36 months was 85%. Grade IV neutropenia was noticed in 15.1% of the patients, grade III-IV neurotoxicity was not encountered, while grade II neurotoxicily was 17%. Gastrointestinal toxicity (mild diarrhea) was seen in 11.3% of the patients. Conclusion: Adjuvant treatment of stage HI colon cancer with the Nordic-FLOX regimen can be an alternative regimen to infusional and other bolus regimens due to its easy administration, lower toxicity, and similar efficacy.